Betaxolol Hydrochloride
Brand Names: Betoptic S, Betoptic
Methodology & AI Transparency ⓘ
Betaxolol Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Betaxolol Hydrochloride (2.8 mg/mL Suspension/ Drops and 10 mg/1 Tablet, Coated; NDC 0078-0729, 10702-013) as a ophthalmic-route beta-adrenergic blocker formulation manufactured/labeled by Novartis Pharmaceuticals Corporation when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Tracked across 20 patient dosage logs with a 79% satisfaction benchmark (RxCUI 308720).
- 3 Typical cash cost range: Dispensing cost comparison spans $32.32 mail/discount cash up to $79.18 uninsured retail (federal NADAC $38.7842).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Betaxolol Hydrochloride: dizziness (7%), headache (5.8%), fatigue (4.5%).
Ask our AI Specialists anything about Betaxolol Hydrochloride
Betaxolol Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Betaxolol Hydrochloride (2.8 mg/mL Suspension/ Drops and 10 mg/1 Tablet, Coated; NDC 0078-0729, 10702-013) as a ophthalmic-route beta-adrenergic blocker formulation manufactured/labeled by Novartis Pharmaceuticals Corporation when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Betaxolol Hydrochloride exerts selective beta-adrenergic blocker pharmacodynamic activity across 2.8 mg/mL Suspension/ Drops and 10 mg/1 Tablet, Coated (ophthalmic-route route, manufactured/labeled by Novartis Pharmaceuticals Corporation), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 0078-0729, 10702-013).
Systemic exposure to Betaxolol Hydrochloride reflects Systemic oral bioavailability of roughly 71%–83% following first-pass transit absorption kinetics and hepatic enzymatic processing and renal clearance proportional to creatinine clearance (betaxolol hydrochloride), sustaining receptor engagement across a Biphasic clearance with 8–21 hr terminal t½ under Betaxolol Hydrochloride maintenance half-life window (initial pharmacodynamic onset within 1–3 hrs (peak cmax) for betaxolol hydrochloride response profile).
Dosing protocols (2.8 mg/mL Suspension/ Drops or 10 mg/1 Tablet, Coated or 20 mg/1 Tablet, Coated or 5.6 mg/mL Solution/ Drops or 0.50% Solution Dropper) balance efficacy (79.00% patient satisfaction across 20 logs) against dizziness (7% of reports), headache (5.8% of reports), fatigue (4.5% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving betaxolol hydrochloride (beta-adrenergic blocker); concurrent restricted medications flagged in section 4/7 of the betaxolol hydrochloride dailymed monograph (308720).
Assess baseline hepatic panels and interacting prescriptions when starting Betaxolol Hydrochloride (beta-adrenergic blocker).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Betaxolol Hydrochloride dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Betaxolol Hydrochloride (beta-adrenergic blocker)
- Concurrent restricted medications flagged in Section 4/7 of the Betaxolol Hydrochloride DailyMed monograph (308720)
Logged Side-Effect Incidence (20 Reports)
Betaxolol Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Betaxolol Hydrochloride)
Human clinical trial evidence for Betaxolol Hydrochloride is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Betaxolol Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $38.7842/unit (~$1163.53/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $32.32 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $79.18 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 20 Anonymous DotMD Community Micro-Logs | $37.17 / mo | View logs ↓ |
Betaxolol Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Betaxolol Hydrochloride RxNorm Concept ID | 308720 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $38.7842 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $79.18 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $32.32 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (20 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Betaxolol Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Cross-verified Betaxolol Hydrochloride (beta-adrenergic blocker) monograph synthesizing RxNorm 308720, openFDA FAERS signals, and $32.32–$79.18 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Betaxolol Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.